Nature's Bioceuticals Finalizes Agreement for the Purchase of Proprietary Weight Loss Formula - (FinancialNewsMedia Wire)

CAPE CORAL, Fla., Nov. 11, 2011 /PRNewswire via COMTEX/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures, Inc. (MILV.pk - News) announced that it has finalized an agreement to purchase all rights to a novel Weight loss formula. The inventor, in order to protect his privacy, has requested that the purchase price not be publicized. With an overall market of over $68 billion in 2010, weight loss is a booming business that continues to grow even in tough economic times. Dieters in the current economy continue to shift to less costly retail and do-it-yourself options such as: meal replacements, OTC diet pills, mail order plans, diet websites, and fad diet books. This trend is very positive for us and we are excited to enter this market by storm. According to government data, 66% of the 229.5 million American adults are now overweight, or 151 million people, of which 71 million are considered obese. These are the people that are in greater and more immediate danger of developing obesity-related health complications such as heart attacks or diabetes. The larger group of 158 million overweight Americans constitutes the share, for whom their overweight condition is not life threatening; i.e. they're concerned with cosmetic weight loss to help them look and feel better. According to surveys of American dieting habits performed by the Calorie Control Council, there are 72 million Americans on some kind of diet program. Male - 40% (28.8 million) Female - 60% (43.2 million). Robert deZanger, CEO of Natures Bioceuticals stated, "We are really excited to enter the weight loss arena with a very special product that will provide people a needed product that will help them lose weight. Our product contains a proprietary blend of natural herbs that has caused weight loss in all people that have tried it. The formula simply curbs the appetite and speeds up the metabolism of those who take it. There is no jittery feeling associated with the product. People who take the formula notice no change in the way they feel. They simply are not as hungry and lose weight. There are many weight loss products on the market and the competition is fierce. We anticipate competition from at least one and probably several new prescription diet drugs that are likely to be approved for sale in the U.S. However, there is an ever increasing trend of people seeking natural remedies as the facts about the dangers of many prescription drugs come to light. Obviously this is a huge market and capturing a small percentage can generate substantial profits for the company. We feel that we have a special product that will be well received and take off as people realize that it works. Further, management feels that the ban by the FDA of products with Ephedra and the negative press on other products containing similar 'stimulants' have left many people desperate to lose weight searching for an alternative." About Nature's Bioceuticals: Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs. Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA". In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC. Media Contact: Financial InsightsPhone Number: 888 656 3509E-mail: investors@naturesbioceuticals.comwww.naturesbioceuticals.com SOURCE Mistral Ventures, Inc. _________________________________________________ DISCLAIMER FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed for Mistral Ventures, Inc. (OTC: MILV), FNMG expects to be paid five thousand five hundred dollars from a non-affiliated third party. FNMG HOLDS NO SHARES OF Mistral Ventures, Inc. (OTC: MILV). This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.